ENSC logo

ENSC Ensysce Biosciences, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$0.41
-0.01 (-2.13%)

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs d…

Market Cap: $7.97Mwww.ensysce.com

Price

No data yet.

Social Signal Score

30
5d
—
30d
—
60d
23
1 mentions
—
90d
36
5 mentions
—
news: 5

Analyst Ratings

2 analysts
Buyconsensus
Strong Buy 0Buy 2Hold 0Sell 0Strong Sell 0

Revenue

$2.18M
$0.00$727.2K$1.45M$2.18M
Sep 2017Sep 2026

Analyst Estimates

FY2025
$-4.73
$-5.48–$-4.17
1 analysts
FY2026
$-0.48
$-0.86–$-0.09
1 analysts
FY2027
$-0.06
$-0.07–$-0.05
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
D. Lynn Kirkpatrick
Sector
Healthcare
Industry
Biotechnology
Employees
9
Beta
1.09
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
-9.08
www.ensysce.com